Vitamin supplementation reduces the progression of atherosclerosis in hyperhomocysteinemic renal-transplant recipients

被引:72
作者
Marcucci, R [1 ]
Zanazzi, M [1 ]
Bertoni, E [1 ]
Rosati, A [1 ]
Fedi, S [1 ]
Lenti, M [1 ]
Prisco, D [1 ]
Castellani, S [1 ]
Abbate, R [1 ]
Salvadori, M [1 ]
机构
[1] Univ Florence, Clin Med Gen & Clin Specialist, Florence, Italy
关键词
D O I
10.1097/01.TP.0000058810.59825.58
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. We previously demonstrated among renal-transplant recipients (RTRs) a high prevalence of hyperhomocysteinemia, which might account for their elevated cardiovascular risk. The purpose of our study was to document, in hyperhomocysteinemic RTRs, the effect of vitamin supplementation on carotid intima-media thickness (cIM), which is an early sign of atherosclerosis. Methods. A total of 56 stable hyperhomocysteinemic RTRs were randomly assigned to vitamin supplementation (folic acid 5 mg/day; vitamin B, 50 mg/day; vitamin 131, 400 mug) (group A) or placebo treatment (group B) for 6 months. All subjects underwent cardiovascular risk-factor assessment, including fasting homocysteine (Hcy) levels assay, and high resolution B-mode ultrasound to measure the intima-media thickness of common carotid arteries, at time of enrollment and after 6 months. Results. Fasting Hcy levels markedly decreased in group A after treatment (21.8 [15.5-76.6] mumol/L vs. 9.3 [5.8-13] mumol/L; P<0.0001), whereas no significant changes were observed in group B (20.5 [17-37.6] mumol/L vs. 20.7 [15-34] pmol/L; P=not significant). In group A, cIMT significantly decreased after treatment (0.95+/-0.20 min vs. 0.64+/-0.17 mm; P<0.0001). All except one patient showed a reduction of cIMT and the mean percentage of cIMT decrease was -32.2+/-12.9%. Patients with methylenetetrahydrofolate reductase (MTHFR) C677T +/+ genotype, with higher Hcy levels, had the major percentage of decrease of Hcy with respect to the other genotypes (mean decrease: MTHFR +/+ 74.8+/-5.7%; MTHFR 58.1+/-10%; MTHFR -/- 56.3+/-8.6%). In hyperhomocysteinemic patients without vitamin supplementation (group B) we documented a significant increase in cIMT after 6 months (0.71+/-0.16 mm vs. 0.87+/-0.19 mm; P<0.05). In 19 of 28 subjects we observed an increase in cIMT, and in 9 of 28 the cIMT was unmodified. The mean percentage of cIMT increase was + 23.3+/-21.1%. Conclusions. Our results demonstrate a beneficial effect of the treatment of hyperhomocysteinemia by vitamin supplementation on cIMT in a group of RTRs.
引用
收藏
页码:1551 / 1555
页数:5
相关论文
共 37 条
  • [1] Abbate R, 1998, THROMB HAEMOSTASIS, V79, P727
  • [2] Anticardiolipin antibody titre and plasma homocysteine level independently predict intima media thickness of carotid arteries in subjects with idiopathic antiphospholipid antibodies
    Ames, PRJ
    Margarita, A
    Alves, JD
    Tommasino, C
    Iannaccone, L
    Brancaccio, V
    [J]. LUPUS, 2002, 11 (04) : 208 - 214
  • [3] Influence of haemodialysis on plasma total homocysteine concentration
    Arnadottir, M
    Berg, AL
    Hegbrant, J
    Hultberg, B
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 1999, 14 (01) : 142 - 146
  • [4] Hyperhomocysteinemia in cyclosporine-treated renal transplant recipients
    Arnadottir, M
    Hultberg, B
    Vladov, V
    NilssonEhle, P
    Thysell, H
    [J]. TRANSPLANTATION, 1996, 61 (03) : 509 - 512
  • [5] Barth JD, 2002, AM J CARDIOL, V89, p32B
  • [6] Determinants of fasting plasma total homocysteine levels among chronic stable renal transplant recipients
    Bostom, AG
    Gohh, RY
    Beulieu, AJ
    Han, H
    Jacques, PF
    Selhub, J
    Dworkin, L
    Rosenberg, IH
    [J]. TRANSPLANTATION, 1999, 68 (02) : 257 - 261
  • [7] High dose B-vitamin treatment of hyperhomocysteinemia in dialysis patients
    Bostom, AG
    Shemin, D
    Lapane, KL
    Hume, AL
    Yoburn, D
    Nadeau, MR
    Bendich, A
    Selhub, J
    Rosenberg, IH
    [J]. KIDNEY INTERNATIONAL, 1996, 49 (01) : 147 - 152
  • [8] Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients - A prospective study
    Bostom, AG
    Shemin, D
    Verhoef, P
    Nadeau, MR
    Jacques, PF
    Selhub, J
    Dworkin, L
    Rosenberg, IH
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1997, 17 (11) : 2554 - 2558
  • [9] Treatment of hyperhomocysteinemia in renal transplant recipients - A randomized, placebo-controlled trial
    Bostom, AG
    Gohh, RY
    Beaulieu, AJ
    Nadeau, MR
    Hume, AL
    Jacques, PF
    Selhub, J
    Rosenberg, IH
    [J]. ANNALS OF INTERNAL MEDICINE, 1997, 127 (12) : 1089 - 1092
  • [10] Excess prevalence of fasting and postmethionine-loading hyperhomocysteinemia in stable renal transplant recipients
    Bostom, AG
    Gohh, RY
    Tsai, MY
    HopkinsGarcia, BJ
    Nadeau, MR
    Bianchi, LA
    Jacques, PF
    Rosenberg, IH
    Selhub, J
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1997, 17 (10) : 1894 - 1900